$MIRM reports strong financial results, potential market expansion in 2023
Mar 8th 2023, 9:03 pm
Analyst Summary: Mirum Pharmaceuticals reported strong financial results for the fourth quarter and year-end of 2022. The company recorded $75.1 million sales of LIVMARLI net product sales in the first full fiscal year of the US launch, achieving its commercial, clinical and regulatory goals. In addition, the company has potential LIVMARLI launches planned in additional international markets, potential label expansion into PFIC and data milestones for its other late-stage clinical programs in 2023. The company looks forward to deepening its global leadership in rare disease and impacting patients who have been waiting for important new medicines. Furthermore, LIVMARLI has shown positive results for Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis patients. LIVMARLI has Breakthrough Therapy designation for both ALGS and PFIC type 2 and an orphan designation for ALGS, PFIC, and biliary atresia. In the pipeline, the company's LIVMARLI and Volixibat products are on track for late-stage development for the treatment of biliary atresia, primary sclerosing cholangitis, and primary biliary cholangitis. Despite the ongoing pandemic, the company's strong financial performance reflects its stable operating expenses and its acquisition of Satiogen.